The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir

This publication has 7 references indexed in Scilit:

• Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies
  Drug Metabolism and Pharmacokinetics, 2005
• CONVERSION OF THE HIV PROTEASE INHIBITOR NELFINAVIR TO A BIOACTIVE METABOLITE BY HUMAN LIVER CYP2C19
  Drug Metabolism and Disposition, 2004
• Ethnic Differences in Genetic Polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1
  Drug Metabolism and Pharmacokinetics, 2004
• Simultaneous Determination of the HIV Drugs Indinavir, Amprenavir, Saquinavir, Ritonavir, Lopinavir, Nelfinavir, the Nelfinavir Hydroxymetabolite M8, and Nevirapine in Human Plasma by Reversed-Phase High-Performance Liquid Chromatography
  Therapeutic Drug Monitoring, 2003
• Treatment Failure of Nelfinavir-Containing Triple Therapy Can Largely Be Explained by Low Nelfinavir Plasma Concentrations
  Therapeutic Drug Monitoring, 2003
• Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study)
  AIDS, 2002
• Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus‐infected patients with chronic liver disease
  British Journal of Clinical Pharmacology, 2000